In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

GLP-1 helps reduce obesity through a number of mechanisms

Clinical studies show GLP-1 drugs, including semaglutide, promote weight loss through a number of effects. These include reduced appetite, slower emptying of the digestive tract, increased insulin production, and more.

How weight loss drugs could reduce obesity costs

A detailed analysis from finance giant ING finds semaglutide and other weight loss drugs could significantly drive down global costs stemming from heart disease and other health problems associated with obesity. The benefits will vary, depending on each country’s demographics and drug and healthcare costs.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

When people stopped using GLP-1, they regained two-thirds of the weight back

Research from 2022 found that when people stopped using the injectable form of the medication, they regained up to two-thirds of lost weight within a year. The finding suggests ongoing treatment will be required for weight loss.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.

Medicare does not pay for GLP-1 for obesity

Coverage for GLP-1s for obesity treatment is limited. It's barred under Medicare, and it's only covered under Medicaid in 13 states as of January 2026, since states can choose whether to cover weight-loss drugs under Medicaid. Coverage with private insurers also remains limited.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

Weight Watchers began offering access to GLP-1 weight loss medications in 2023 after losing more than 1.5 million members over the previous two years.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for)

Glucagon-like peptide-1, or GLP-1, is one of the most well-known peptides in common use. In 2024, 26.5% of all adults with diagnosed diabetes used the substance. GLP-1 was particularly popular among people with diabetes aged 50-64, followed by younger adults and then seniors aged 65+.

From Ozempic to Wegovy, see the $58B weight loss drug market visualized in one chart.

The popularity of new weight loss drugs has led to a diabetes treatment shortage

The FDA approved Ozempic to help patients with diabetes, but the popularity of semaglutide as a weight loss drug led doctors to prescribe Ozempic to nondiabetic patients who needed to lose weight. Ozempic became so popular that manufacturers could not keep pace with demand, posing risks for Ozempic-users with diabetes.

How self-care led to Ozempic's success

Self-care has become a $1.5T economy that idealizes restraint and willpower, leaving behind those who can't shake off human nature. This article explores how Ozempic and similar weight loss medications pick up where self-care left off.

GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva

Scientists studying the barely-there feeding frequency of the Gila monster found its saliva had a hormone regulating blood sugar and appetite. Further research revealed this hormone resembled a human one known as GLP-1, giving rise to the modern wave of diabetes and weight-management drugs.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

Obesity rates have more than doubled worldwide since 1990

In the US alone, the percentage of the population meeting the clinical standard of obesity rose from less than 20% to more than 40% over the past three decades. This rise has been matched by many countries across the globe, from industrialized to developing nations.

Hormone and peptide compounds imported from China soared in 2025

US customs data indicates that these imports doubled to $328M in the first three quarters of 2025, from $164M in the same period of 2024. The imports include GLPs, among other products. (Some users may experience a paywall.)

An overview of 200 years of diabetes treatment

Diabetes treatment became truly effective after the advent of insulin injections in the early 1900s. Diabetes is becoming increasingly common. Current trends estimate one in three Americans will have diabetes by 2050. This overview explores two centuries of diabetes treatment—starting in 1812—and outline potential challenges to treatment and prevention.

Explore an animated list of nine scientific breakthroughs funded by NASA, the NSF, and the NIH

Among the technologies made possible by the National Science Foundation and the National Institutes of Health were the CAPTCHA digital puzzles to block bots from accessing sites, the set of diabetes and obesity drugs that fall under the umbrella of GLP-1 receptor agonists, and various cordless appliances, including the handheld vacuum cleaner. (Some readers may experience a paywall.)

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

How meal timing factors into health outcomes

The world is trending toward weight gain, a development that comes with a corresponding rise in risk for health conditions, including diabetes and heart disease. This article explores how meal timing has become a factor in nutrition and weight maintenance.

History's weirdest weight loss fads, fact-checked

Nothing catches popular attention more than a claim to have found a quick weight-loss technique. History shows us such claims are often unfounded. Dr. Michael Mosley explores extreme weight-loss tips from history, from tapeworms to vinegar diets.

The dietary market is worth more than $60B

Listen to this question and answer session with the US Food and Drug Administration about dietary supplements—vitamins, minerals, probiotics and similar products people may buy in liquid, pill, or powder form. They are categorized legally as a category of food and can be legally brought to market without the FDA even knowing about it, though consumers can tell FDA about issues with the products and FDA can take action to remove dangerous or unlawful items after they're available.

In 2023, the world consumed over 5 billion pizzas

Americans ate 3 billion of those, leading to sales that reached $43.3B, according to industry analysts at Gitnux. They estimated that Americans eat an average of 46 slices per person that year.

Opioid epidemic 101: lawsuits and settlements

State and local governments trying to address the opioid epidemic have sued organizations they believe started and supported the crisis. Companies that made, distributed, or contributed to sales of the highly addictive painkillers are expected to pay more than $50B in settlements. These settlements specifically state that at least 85% of settlement funds must be spent on addressing the epidemic, though where exactly the money is going is unclear.

In 2025, American tech companies will spend $300B to $400B on AI

That is, in nominal dollars, more than any group of companies has ever spent to do anything. Notably, these companies are not remotely close to earning $400B on artificial intelligence.

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

Genetic drug matching, called pharmacogenomics, can help avoid dangerous drug reactions

Certain gene variants can affect how quickly or slowly medications are broken down in the body, affecting drug effectiveness and the risk of drugs failing. Such testing is often not covered by insurance companies though research indicates if these tests were performed for more than six drugs across the US population, avoided ailments would likely climb into the hundreds of thousands. (Some users may encounter a paywall.)

Ultra-processed foods are made to maximize cravings and encourage overeating

Often disguised as healthy options like granola bars and low-fat yogurt, these foods silently fuel chronic diseases, despite dominating diets. Reviewing labels for ingredients like stabilizers and emulsifiers can serve as indicators to help identify these products.

Inhalers, antihistamines, immunotherapy, and more have made allergies a multimillion-dollar market

Market research suggests that the allergies market will continue to grow in the years ahead as the number of allergy diagnoses increases, identifying new patients. Areas of growth include the increasing interest in immunotherapies designed to retrain the immune system through regular exposure to potential allergens via injections and under-the-tongue medical formulations, among other approaches.

Can we speed up our metabolisms?

Listen to this 31-minute podcast to better understand what science knows and doesn't know about metabolism, as well as the only thing that seems capable of changing it. Scientists understand that the difference between a so-called “fast” and “slow” metabolism does not affect one’s ability to lose weight.

In 2024, the US had more organ transplants than ever before—besting the 2023 record

More than 48,000 organ transplants were performed in 2024, and about 46,630 were performed in 2023. These record highs are illustrated here as part of data from 1988 to partway through 2025. Kidneys, livers, and the heart remain the most common transplanted organs. (Some users may encounter a paywall.)

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

Superbugs could claim 1.9 million lives per year by 2050

The increased use of antibiotics combined with an aging population, is projected to result in an almost 50% increase in global deaths from antimicrobial resistance each year. At the same time, antibiotic use for livestock is expected to increase by 30% over the same time frame.

Drugs in space: the pharmacy orbiting the Earth

Researchers are developing pharmaceutical solutions for astronauts, whose bodies may not respond the same way in space as they would on Earth. Similar to how microgravity causes changes to astronaut physiology, the environmental shift enables new...

Menopause may become a $600B industry

Companies marketing products and supplements to alleviate menopause symptoms and make life easier during this life stage have become a gold mine. This 2022 article explores how and why companies have swooped into this space, and whether you should trust them or not.

'Menobelly' is real, with more fat stored around the abdomen as estrogen levels drop

The way fat is carried in the body shifts with menopause, with those pounds increasingly settling around the abdomen instead of the hips and thighs. Exacerbating this phenomenon, muscle mass also begins to decline, so calories stick around longer than usual. Resistance training, including push-ups and planks, alongside a heavier protein diet can help.

Biotech is trying to boost drug production efficiency—using chicken eggs

A company called Neion Bio is genetically engineering birds in a bid to produce medical compounds, a herculean task that scientists have struggled with for decades. The US FDA has approved only one chicken-derived drug in the past—an expensive treatment for a rare liver disorder. (Some users may encounter a paywall.)

Americans spent $6.6 billion on body odor products in 2023

This high figure from Euromonitor, a research firm, suggests Americans spent more on deodorant than in any other country. Beyond deodorant, there's also growing interest in "whole body" deodorant designed to mask smells from various parts of the body beyond the armpit.

The eight habits that could add up to 24 years to your life

A study presented at the American Society for Nutrition's annual meeting revealed that adopting eight healthy lifestyle habits in middle age can significantly increase life expectancy. The habits include being physically active, avoiding opioid...

The US loses roughly $400B a year in productivity due to sleep deprivation

For an article about a woman who built a business empire telling bedtime stories, the Hustle created this graphic showing the estimated GDP loss associated with chronic insomnia. The United States had a much more significant loss than other countries.

Why there's a snack recession

Inflation and economic uncertainty have driven many Americans to make cuts to their snack budgets, according to reports from major food manufacturers like General Mills, JM Smucker, and Campbell's. Major retailers have also observed lower-income consumers cutting back on nonessentials due to the macroeconomic environment.

One estimate values concierge services at $38.9B by 2032

Data Horizons Research put the value of this global market at $18.9B in 2021, but anticipates massive growth by 2032, with North America comprising the majority of the market. Chronic health conditions, their analysis suggests, will be a contributing factor to this growth as medically complex individuals seek more personalized care.